补髓生血颗粒对慢性再生障碍性贫血患者骨髓基质细胞碱性成纤维细胞生长因子及其受体的影响

Effects of Busui Shengxue Granule on bFGF and bFGFR in Bone Marrow Derived Stroma Cells of Chronic Aplastic Anemia Patients

目的观察补髓生血颗粒对治疗慢性再生障碍性贫血(chronic aplastic anemia,CAA)患者的临床疗效及骨髓基质细胞相关细胞因子的影响。方法将124例CAA患者按随机数字表法分为两组,试验组(61例)使用补髓生血颗粒治疗,对照组(63例)使用再造生血片治疗,疗程均为6个月,并设立10名健康人作为正常对照组。观察患者治疗前后症状积分、疗效判定与外周血象的变化,采用RT-PCR法检测CAA患者治疗前后骨髓基质细胞中碱性成纤维细胞生长因子(b-fibroblast growth factors,bFGF)及碱性成纤维细胞生长因子受体(b-fibroblast growth factors receptor,bFGFR)信使RNA(messenger RNA,mRNA)表达变化。结果试验组总有效率(75.0%,45/61)明显优于对照组(58.7%,37/63),其症状积分及外周血象明显改善,也明显优于对照组(P<0.05)。CAA患者骨髓基质细胞bFGF及bFGFRmRNA表达水平较正常对照组明显降低(P<0.05),治疗后两组bFGF与bFGFRmRNA表达水平均有所提高(P<0.05,P<0.01),且试验组优于对照组(P<0.05,P<0.01)。结论补髓生血颗粒具有较好的临床疗效,能改善CAA患者症状积分以及外周血象,提高临床疗效,且对细胞因子bFGF与bFGFRmRNA表达水平有调节作用,通过调控CAA骨髓基质细胞的增殖和定向分化以及促进骨髓新生血管的形成改善了造血微环境,促进骨髓造血功能的恢复。

Objective To observe the therapeutic effects of Busui Shengxue Granule （BSSXG） on chronic aplastic anemia （CAA） patients and its effects on bone marrow derived stroma cells （BMDSCs） correlated cytokines. Methods One hundred and twenty-four patients with CAA were randomly assigned to two groups according to the random digit table. Patients in the test group （61 cases） were treated with BSSXG, while those in the control group （63 cases） were treated with Zaizao Shengxue Tablet （ZST）. The therapeutic course was 6 months for all. Besides, 10 healthy subjects were recruited as the normal control group. Changes of the symptom integral, therapeutic efficacy judgment, and changes of peripheral hemogram of patients were observed. The mRNA expression of bfibroblast growth factors （bFGF） and b-fibroblast growth factors receptor （bFGFR） were detected by reverse transcription PCR. Results The total effective rate of the test group was 75.0% （45/61）, higher than that of the control group （58.7%, 37/63）. Its symptom integral and peripheral hemogram were obviously improved, better than those of the control group （ P 〈 0.05, P 〈 0.01 ）. The mRNA expressions of bFGF and bFGFR of the test group were obviously lower than those of the normal control group （P〈0. 05,P〈0. 01 ）. They were somewhat improved after treatment in the two groups, with better results obtained in the test group. Conclusions BSSXG showed better clinical effects. It could improve the symptom integral and peripheral hemo- gram of CAA patients, improve the clinical efficacy, and regulate the expression levels of bFGF and bFGFR. It improved the hematopoietic microenvironment and promoted the hematopoiesis of the bone marrow through regulating the proliferation and oriental differentiation of stroma cells, and promoting the bone marrow angiogenesis.